Helperby Therapeutics announces phase 1 results demonstrating multiple benefits of its unique combination antibiotic therapy

  • The combination is azidothymidine (AZT), which is a new class antibacterial, and low dose colistin.
  • The combination is active against all three WHO Critical Priority Carbapenem Resistant Pathogens.
  • In addition, AZT and colistin act synergistically against carbapenem and colistin-resistant Enterobacteriaceae (CRE) infections.

Click here to read the press release